All News

RheumNow Podcast square

Mono- and Oligo- are Different (8.18.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

Read Article
renal.genes_.jpg

Imaging Mass Cytometry to Study Lupus Nephritis

EurekaAlert!

Lupus researchers from the University of Houston are reporting the first use of the powerful imaging mass cytometry to examine the kidneys of patients with systemic lupus erythematosus, as a means of diagnosing lupus nephritis in SLE patients.  LN is a severe inflammation of the kidneys and a major cause of death in lupus patients. Up to 60% of SLE patients will develop renal symptoms with 5–20% of those patients progressing to end stage kidney disease within 10 years. 

Read Article
RheumNow Podcast square

English for the Biologically-Challenged (8.4.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Read Article
Man in window

Unrecognized Mental Health Problems in Autoimmune Diseases

Jack Cush, MD

More than half of patients with auto-immune conditions experience mental health conditions such as depression or anxiety, yet the majority are rarely or never asked in clinic about mental health symptoms, according to new research from the University of Cambridge and King’s College London.

Read Article
RheumNow Podcast square

"Ask Cush Anything" Returns (7.21.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"

Read Article
Both Lupus Nephritis and Cutaneous lupus erythematosus (CLE) show evidence of tissue infiltrating T cells expressing hi amouts of hypoxia-inducible factor-1 (HIF-1); HIF-1 inhibition improves skin/systemic disease & decreases T cell cytotoxic activity https://t.co/Yv2K5UKjUV https://t.co/sbfLl7ZUqh

Links:

Dr. John Cush RheumNow ( View Tweet)
HEALTH DISPARITIES: Lancet study shows from 2000-2019, all-cause mortality was signif. higher in the American Indian/Alaska Native (1028/100K) & Blacks (953·/100K) compared to Whites (802); but lower in Asians (442) & Latinos (595) https://t.co/g8Z3h6BYw8 https://t.co/Ckz1L3O0W7

Links:

Dr. John Cush RheumNow ( View Tweet)
Hong Kong study shows Very low dose prednisolone (<5 mg/d) doesn't confer excessive CV risk. 2 233 RA pts (105 826 Pt-years FUV; mean duration 8.7 yrs) - 7% developed MACE. MACE risk incr 7% per month in those taking ≥5 mg pred. https://t.co/lcehOgaqCQ https://t.co/AhWGnUuYcc

Links:

Dr. John Cush RheumNow ( View Tweet)
Spanish study of 518 #SLE patients, 7% of whom received at least one dose of rituximab(26) or belimumab (11). RTX given for either hemolytic anemia or ITP (11 pts), nephritis & CNS SLE (5 pts ea). BEL mostlyfor arthritis (8 pts) https://t.co/IqCVfOL5rb https://t.co/ocLj7Ejs7A

Links:

Dr. John Cush RheumNow ( View Tweet)
New Full Length from A&R: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexelimab in Systemic Lupus Erythematosus with Exploration of Response Based on Gene Pathway Co-Expression Patterns https://t.co/5pzBfiZaNt Created with https://t.co/L5O6lHuNSY https://t.co/HvDy4b1Bg3

Links:

ACR_Journals ACR_Journals ( View Tweet)
SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/iPhecsJeJX https://t.co/0TIy2hsPC1

Links:

Dr. John Cush RheumNow ( View Tweet)
Voclosporin in SLE - Long-Term Safety and Efficacy The AURORA 2 study evaluated the long-term safety and efficacy of VOC upus nephritis (LN) patients and, after 3 years, demonstrated long term safety and efficacy following the one-year AURORA 1 study. https://t.co/YmKLuhyCVG https://t.co/X2u9iCckt7

Links:

Dr. John Cush RheumNow ( View Tweet)
Unrecognized Mental Health Problems in Autoimmune Diseases More than half of patients with auto-immune conditions experience mental health conditions such as depression or anxiety, yet most are rarely asked in clinic about mental health symptoms. https://t.co/wxuGmuPh7D https://t.co/jMZkH1SIcS

Links:

Dr. John Cush RheumNow ( View Tweet)
Structured interviews from 462 pts from Michigan SLE clinic. 22% admit to cost-related non-adherence (CRNA) over 12 mos. CRNA associated signif. higher levels SLE disease activity & more lupus damage. Worse scores in those with Fibromyalgia https://t.co/NHIIqmWVqJ https://t.co/zX4gTFTcW7

Links:

Dr. John Cush RheumNow ( View Tweet)
RNase Treatment of Autoimmune Disorders U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders. https://t.co/JhOk4rEdoG https://t.co/E8UxJ94ShN

Links:

Dr. John Cush RheumNow ( View Tweet)
Horizon announced its phase II RCT of Daxdilimab (anti-ILT7 mAB targeting dendritic cells) failed to meet its primary endpoint - BICLA response w/ pred ≤7.5 mg/day @wk48 (DAX=PBO). DAX also under study in alopecia areata, DLE, lupus nephritis https://t.co/4EH6rBS0sJ https://t.co/B1uceAPGTB

Links:

Dr. John Cush RheumNow ( View Tweet)
Voclosporin in SLE - Long-Term Safety and Efficacy The AURORA 2 study evaluated the long-term safety and efficacy of VOC upus nephritis (LN) patients and, after 3 years, demonstrated long term safety and efficacy following the one-year AURORA 1 study. https://t.co/uiqi8J9rrP https://t.co/3r6aAI3WTj

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE and Pregnancy Outcomes Obstetric complications and poor pregnancy outcomes are not uncommon in women with systemic lupus erythematosus (SLE), especially with active disease. https://t.co/ojFccY6kTT https://t.co/kJpIZP1kSd

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/vGt12ul6iy https://t.co/044BScmSYc

Links:

Dr. John Cush RheumNow ( View Tweet)
Infectious Risk with B Cell Therapies in Lupus A UK registry study of moderate to severe SLE showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy. https://t.co/AbqrlU3qpw https://t.co/RlyWaTjWO1

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×